Apr 24 |
REGENXBIO to Participate in Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
|
Apr 17 |
REGENXBIO Inc.'s (NASDAQ:RGNX) recent 7.9% pullback adds to one-year year losses, institutional owners may take drastic measures
|
Mar 28 |
REGENXBIO Sees Positive Results For Macular Degeneration Therapy
|
Mar 28 |
REGENXBIO Announces Lancet Publication of Phase I/IIa Study Evaluating ABBV-RGX-314 as a One-Time Gene Therapy for Wet AMD
|
Mar 27 |
REGENXBIO to Participate in Cantor Fitzgerald's Virtual DMD and Other Dystrophy Days
|
Mar 18 |
Regenxbio Inc (RGNX) President and CEO Kenneth Mills Sells 15,000 Shares
|
Mar 13 |
Does This 1 New Threat Make Sarepta Therapeutics Stock Worth Selling?
|
Mar 11 |
Regenxbio: DMD Program Lends Additional Credibility To NAV Technology Platform
|
Mar 11 |
REGENXBIO to Participate in Upcoming Investor Conferences
|
Mar 8 |
Regenxbio raised to Buy at RBC on pivot to Duchenne
|